Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature.
With the arrival of new, more expensive vaccines, economic evaluation has become an important tool for assessing the feasibility of introducing a new vaccine into a country's routine immunization schedule. Haemophilus influenzae type b (Hib) vaccine has been available since the early 1990s, but uptake of the vaccine was slow in low-income countries until the GAVI Alliance started offering financial support for it. However, at some point, GAVI Alliance-supported countries will have to identify other sources of financing for Hib vaccine, meaning cost-effectiveness evidence will be important to support resource allocation decisions. Several middle-income countries have not yet introduced the vaccine. Thus, the aim of this literature review was to identify and evaluate the published evidence on the cost-effectiveness of the Hib vaccine, with particular emphasis on low- and middle-income countries. It is concluded that there are only few studies available from resource-poor countries and some of these are of low quality.
Griffiths
Ulla K
UK
Hib Initiative, Health Policy Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. ulla.griffiths@lshtm.ac.uk
Miners
Alec
A
D003362:Cost-Benefit Analysis; D003906:Developing Countries; D017850:Economics, Pharmaceutical; D006192:Haemophilus Infections / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000191:economics* / Q000627:therapeutic use; D019741:Haemophilus influenzae type b / Q000276:immunology; D006801:Humans; D017589:Immunization Programs
D018073:Haemophilus Vaccines